| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.24 | 5e-07 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-06 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.12 | 6e-05 |
| mRNA | leptomycin B | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.2 | 0.0004 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0007 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0007 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.16 | 0.001 |